Haemonetics Corporation (NYSE:HAE) disclosed today that Josep Llorens, the Executive Vice President responsible for global manufacturing and supply chain, is planning his retirement. Llorens is set to officially retire on July 11, 2025. During the interim, he will maintain his executive responsibilities while the company initiates a search for his replacement, assisting President and CEO Chris Simon with the transition process thereafter.
“The contributions Mr. Llorens has made throughout his tenure are deeply appreciated,” noted Haemonetics in a filing submitted to the SEC.
Llorens’ retirement news follows a vigorous 2024 for Haemonetics. The organization embarked on a substantial merger and acquisition endeavor by purchasing Attune Medical, along with its ensoETM active esophageal cooling technology, for $160 million. This transaction closely followed Haemonetics’ acquisition of OpSens, a company specializing in cardiology devices, at the end of 2023.
Additionally, 2024 saw regulatory successes for Haemonetics, including receiving FDA approval for the TEG 6s hemostasis analyzer system assay cartridge. The company also unveiled its new Vascade MVP XL mid-bore venous closure device.
Nevertheless, in the autumn, the company confirmed with the state of California about a facility shutdown impacting 75 employees, aligning with Haemonetics’ announcement in November 2023 to phase out its blood inline collection operations, which are part of the Blood Center business division. Consequently, this decision also ceased related manufacturing processes.
Haemonetics concluded the year by agreeing to divest its whole blood segment to GVS S.p.A for $67.1 million in December.